Adem Albayrak

VP of Technology, Life Sciences Business

Adem Albayrak has spent his career in the space of genomics, clinical research, and precision medicine across both industry and academia. Adem spearheaded software product development at Knome, the first company to commercialize whole genome sequencing and interpretation to accelerate the process of moving from big data to insights. Adem then led product management at BIOBASE, a biological knowledgebase company, where he launched a pharmacogenomics data product which was eventually acquired by Qiagen. Afterwards, he moved on to the Dana-Farber Cancer Institute where he oversaw the hospital’s genomics data pipeline that enabled clinical research and translational medicine; supported researchers in bioinformatics and analytics projects; and headed up product management for the enterprise that included software for IRB-approved research data delivery, clinical data abstraction that leverages machine learning and data visualization, and more. Adem now leads Technology within Health Catalyst’s Life Sciences Business, tying together data engineering, clinical analytics, data science, and product development to enable our clients to work better with providers.

See content from Adem Albayrak

Data-Driven Precision Medicine: A Must-Have for the Next-Generation of Personalized Care

Under a precision medicine approach, clinicians, academics, and pharma and biotech researchers and regulators aim to deliver the right drug for the right patient at the right time. Data, however, can present a challenge to precision medicine goals due to gaps in clinical care, research, and drug development when organizations don’t have the ability to capture and report on relevant real-world data. With the right systems to collect and share clinical and molecular data, the healthcare industry can realize the full benefits of precision medicine.

This site uses cookies

We take pride in providing you with relevant, useful content. May we use cookies to track what you read? We take your privacy very seriously. Please see our privacy policy for details and any questions.